Co-Founder and Member of Management Team: 2007 - present

Amalyte Pharmaceuticals, Palo Alto, CA

- Evaluated an in-licensing pre-clinical candidate opportunity for multiple clinical indications in gastrointestinal (GI) inflammatory (IBD and IBS) and in allergic (rhinitis and asthma) diseases as the basis for Amalyte feasibility.

- Assisted with the design of 2 research programs focused on polycystic kidney disease and inflammation.

- Drafted 5 provisional applications.

- Company was acquired by Kemin Industries in June 2009.

 

Chemistry Group Leader: 2003 - 2004

Senomyx, Inc., San Diego, CA

Umami Agonist Project - Chemistry group leader.

- Led a team of 2-6 medicinal chemists.

- Directed team in the development of agonists to the T1R1/T1R3 GPCR.

- Several compounds were selected for evaluation in a collaborator's products. One compound was selected for product launch in July 2007.

 

Medicinal Chemistry Group Leader: 1999 - 2003

Chugai Pharma USA LLC., a member of the Roche Group, San Diego, CA

Akt/PKB Kinase Project (Dec. 2002-Apr. 2003) - Chemistry group leader on kinase targets for cancer

- Led a team of 5 medicinal chemists to investigate 3 HTS hits.

- Transformed initial micromolar HTS hit into a selective low nanomolar inhibitor in less than 2 months

- Lead compounds demonstrated functional efficacy in cell-based assays

Vitamin D3 Agonist Project (May 2001-Nov. 2002) - Chemistry group leader on a nuclear hormone receptor target for cancer and bone diseases

- Led a team of 4 medicinal chemists in collaboration with Chugai Japan's chemists and biologists

- Conducted overseas meetings and videoconferences with Japanese scientists

- Directed team in the development of Chugai's first non-secosteroidal small molecule agonist with activity equal to 1?,25-dihydroxyvitamin D3

Malonyl-CoA Decarboxylase (MCD) Project (Aug. 1999-Apr. 2001)

- Initiated SAR studies on two HTS hits in a cardiovascular program aimed at developing an orally available small molecule drug for the treatment of stable angina

- Transformed one lead from high nanomolar to low nanomolar potency, a member of which was the first selected for in-vivo efficacy studies

- Devised strategies for SAR studies, which utilized solution phase combinatorial chemistry techniques

 

Senior Research Scientist: 1997 - 1999

Chugai Biopharmaceuticals, Inc., San Diego, CA

AP-1 Project (Jul. 1998-Jul. 1999)

- Designed and synthesized low nanomolar TNF-? (AP-1/NF-kB) inhibitors based on benzopyran and coumarin core structures

Combinatorial Library Generation(Sep. 1997-Jun. 1998)

- Developed synthetic methodologies for use in parallel solution and solid phase libraries (e.g., oxazoles, 1,2,4-triazoles and 3-thiazolo-1,2,4-triazoles)

- Played a key role in combinatorial chemistry technology transfer from Eli Lilly/Sphinx Pharmaceuticals to Chugai

 

Research Scientist: 1992 - 1996

Chugai Biopharmaceuticals, Inc., San Diego, CA

Combinatorial Chemistry (Aug. 1996-Aug. 1997)

- Applied combinatorial chemistry through use of parallel or split-mix methods to synthesize small molecule libraries for the identification of novel therapeutic leadss

Nucleoside and Nucleotide Chemistry (Oct. 1992-Jul. 1996)

- Devised new strategies for synthesis of complex heterocycles of therapeutic interest (e.g., mono-, bi-, and tri-cyclic N-, O-, and S- heterocycles, nucleosides and nucleotides)

- Performed asymmetric synthesis of enantiopure cyclopentanes leading to modified carbocyclic nucleosides

- Led a team of 2 research assistants and two research associates in the synthesis of modified DNA oligonucleotides on scales of 1 - 2000 micromoles

 

Staff Scientist: 1983 - 1986

Eastman Kodak, Dayton, OH

- Performed inorganic and organic analyses of electroplating baths. Developed statistically more efficient methodology for the analysis of organic additives in nickel electroplating solutions. Experimented with a variety of nickel electroplating solutions and metallurgical stress research using organic additives.

 

Graduate Research: 1987 - 1992.

University of California, Davis

- Designed and implemented first regiospecific synthesis of unsymmetrical tetraarylporphyrins.

- Devised synthetic methodologies to pyrrole building blocks (e.g., 2,5-substituted pyrroles, fully substituted pyrroles, dipyrromethanes, and a,c-bilidienes) that were used in the synthesis of porphyrins, chlorins, and related heterocyclic macrocyclic compounds.

- Performed natural product isolation and modification of chlorophyll-a.

 

Undergraduate Research: 1984 - 1985

Wright State University, Dayton, OH

- Research involved synthesis of aromatic intermediates leading to novel fused ring sydnones and aromatic dimers with one or more sydnone substituents

EDUCATION:

Ph.D. in Organic Chemistry

University of California, Davis

- Professor Kevin M. Smith, Research Advisor

- Dissertation: "Syntheses of Regiospecifically Substituted Unsymmetrical Tetraarylporphyrins and Novel Di- and Tetra-pyrrole Systems"

- Degree Received: 1992

B.S. in Chemistry

Wright State University, Dayton, OH

- Major: Chemistry (with an emphasis in biology)

- Degree Received: 1985

PATENTS

1. "Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseases", Arrhenius, T.; Cheng, J-F; Wilson, M. E.; Serafimov, R.; Nishimoto, M.; Wallace, D. M.; Tith, S.; Brown, S. J.; Harmon, C. S.; Lopaschuk, G. D.; Dyck, J. R., U.S. Patent 7,723,366, May 25, 2010.
2. "Coumarin Derivatives useful as TNF-a Inhibitors"; Cheng, J-F; Arrhenius, T.; Wallace, D.; Chen, M.; Tith, S.; Kashiwagi, H.; Ono, Y.; Watanabe, Y., U.S. Patent 7,709,664, May 4, 2010.
3. "Novel Methods for Production of 5-Epi- -vetivone, 2-Isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-Isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one"; Julien, B.; Wallace, D. M.; U.S. Patent 7,622,614, November 24, 2009.  
4. "Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators"; Arrhenius, T.; Chen, M.; Cheng, J-F; Huang, Y.; Nadzan, A.M.; Penuliar, R. J.; Wallace, D. M.; Zhang, L.; Lopaschuk, G.D.; Dyck, J.R.; U.S. Patent 7,524,969, April 28, 2009.  
5. "Method for preparing imidazole derivatives"; Arrhenius, T.; Chen, M.; Cheng, J-F; Huang, Y.; Nadzan, A.M.; Tith, S.; Wallace, D. M.; Brown, S.J.; Harmon, C. S.; Zhang, L.; Lopaschuk, G.D.; Dyck, J.R.; U.S. Patent 7,385,063, June 10, 2008.  
6. "Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators"; Arrhenius, T.; Chen, M.; Cheng, J-F; Huang, Y.; Nadzan, A.M.; Tith, S.; Wallace, D. M.; Liu, B.; Nishimoto, M.; Lopaschuk, G.D.; Dyck, J.R.; U.S. Patent 7,279,477, October 9, 2007. 
7. "Coumarin Derivatives useful as TNF- Inhibitors"; Cheng, J-F; Arrhenius, T.; Wallace, D.; Chen, M.; Tith, S.; Kashiwagi, H.; Ono, Y.; Watanabe, Y., U.S. Patent 7,026,491, April 11, 2006.  

 

PATENT APPLICATIONS

 

1. "Novel Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one", Julien, B. N.; Wallace, D. M.; US Patent Appl. US20100129306, May 27, 2010.
2. "Polybasic Bacterial Efflux Pump Inhibitors and Therapeutic Uses Thereof Glinka, T.; Rodny, O; Bostian, K. A.; Wallace, D. M.; Higuchi, R.; Chow, C.; Mak, C. C.; Hirst, G.; Eastman, B.;  PCT Int. Appl. WO WO2010/05410, May 14, 2010; US Patent Appl. 20100152098, June 17, 2010.
3. "Novel Flavors, Flavor Modifiers, Tastants, Taste Enhancers, Umami or Sweet Tastants, and/or Enhancers and Use Thereof"; Tachdjain, C.; Patron A. P.; Adamski-Werner, S. L.; Bakir, F.; Chen, Q.; Darmohusodo, V.; Hobson, S. T.; Li, X.; Qi, M.; Rogers, D.; Rinnova, M.; Servant, G.; Tang, X-Q; Zoller, M.; Wallace, D.; Xing, A.; Gubernator, K.;U.S. Patent Appl. 20090111834, April 30, 2009. 
4. Polybasic Bacterial Efflux Pump Inhibitors and Therapeutic Uses Thereof" Glinka, T.; Lomovskaya, O; Bostian, K.; Wallace, D. M.; PCT Int. Appl. WO 2008/141010, November 20, 2008; U.S. Patent Appl. 20080318957, December 25, 2008. 
5. "Quaternary Alkyl Ammonium Bacterial Efflux Pump Inhibitors and Therapeutic Uses Thereof" Glinka, T.; Lomovskaya, O; Bostian, K.; Wallace, D. M.PCT Int. Appl. WO 2008/141012, November 20, 2008.
6. "Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators"; Arrhenius, T.; Chen, M.; Cheng, J-F; Huang, Y.; Nadzan, A.M.; Tith, S.; Wallace, D. M.; Liu, B.; Nishimoto, M.; Lopaschuk, G.D.; Dyck, J.R.; U.S. Patent Appl. 20080070869, March 20, 200
7. "Bisphenyl Compounds Useful As Vitamin D3 Receptor Agonists"; Wallace, D.; Arrhenius, T.; Russell, A.; Liu, D.; Xing, A.; Tith, S.; Hou, Z.; Tadakatsu, T.; Ono, T.; Kashiwagi, H.; Shimizu, K.; Ikura, H.; U.S. Patent Appl. 20060025474, February 2, 2006. EP 1740522 A2, January 10, 2007. 
8. "Compounds Comprising Linked Heteroaryl Moieties and Their Use as Novel Umami Flavor Modifiers, Tastants and Taste Enhancers for Comestible Compositions"; Wallace, D., Tachdjain, C.; Lebl-Rinnova, M.; PCT Int. Appl. WO 2006/084186, October 8, 2006.; US Patent Appl. 20060263411, November 23, 2006. 

 

1. "Malonyl coenzyme A decarboxylase (MCD) as a target for prophylaxis and treatment of ischemic heart diseases", Cheng, J-F; Wallace, D.; Nadzan, A.; Lopaschuk, G. D. Drugs of the Future, in preparation.
2. "Benzo and Pyrido Fused Azole Compounds as Potent Inhibitors of Malonyl-CoA Decarboxylase", Cheng, J-F; Wilson, M.; Kafka, M.; Chen, M.; Liu B.; Mak C.C.; Huang, Y.; Wallace, D.; Tith, S.; Arrhenius, T.; Nadzan, A. J. Med. Chem., in preparation.
3. "Chemical Modification of a Lignin Model Polymer via Arylboronate Ester Formation Under Mild Reaction Conditions", Korich, A. L.; Clarke, K. M.; Wallace, D.; Iovine, P.M., Macromolecules, 2009, 42(16), 5906-5908. 
4. "Novel trifluoroacetophenone derivatives as malonyl-CoA decarboxylase inhibitors ", Wallace, D.; Cheng, J.-F.; Arrhenius, T.; Nadzan, A. M., Bioorg. Med. Chem. Lett. 2007, 17(4), 1127-1130. 
5. "Heteroaryl Substituted Bis-Trifluoromethyl Carbinols as Malonyl-CoA Decarboxylase Inhibitors", Cheng, J.-F.; Mak, C. C.; Huang, Y.; Penuliar, R.; Nishimoto, M.; Zhang, L.; Chen, M.; Wallace, D.; Arrhenius, T.; Chu, D.; Yang, G.; O'Leary, E.; Barbosa, M.; Dyck, J. R. B.; Lopaschuk, G. D.; Nadzan, A. M., Bioorg. Med. Chem. Lett. 2006, 16(13), 3484-3488.  
6. "Synthesis and Structure-Activity Relationship of Small-Molecule Malonyl Coenzyme A Decarboxylase Inhibitors", Cheng, J.-F.; Chen, M.; Wallace, D.; Tith, S.; Haramura, M.; Liu, B.; Mak, C. C.; Arrhenius, T.; Reily, S.; Brown, S.; Thorn, V.; Harmon, C.; Barr, R.; Dyck, J.R.B.; Lopaschuk, G.D.; Nadzan, A. M. J. Med. Chem. 2006, 49(5), 1517-1525.  
7. "Malonyl CoA Decarboxylase Inhibition Protects the Ischemic Heart by Inhibiting Fatty Acid Oxidation and Stimulating Glucose Oxidation", Dyck, J. R. B.; Cheng, J-F; Stanley, W.C.; Barr, R.; Chandler, M. P.; Brown, S.; Wallace, D.; Arrhenius, T.; Harmon, C.; Yang, G.; Nadzan, A.; Lopaschuk, G. D.   Circulation Research 2004, 94(9), e78 - e84.
8. "Discovery and Structure-Activity Relationship of Coumarin Derivatives as TNF- Inhibitors", Cheng, J-F; Chen, M.; Wallace, D.; Chen, M.; Tith, S.; Arrhenius, T.; Kashiwagi, H.; Ono, Y.; Ishikawa, A.; Sato, H.; Kozono, K.; Sato, H.; Nadzan, A.  Bio. Med. Chem. Lett. 2004, 14(10), 2411-2415.
9. "Syntheses and Some Chemistry of 1,2- and 1,1-Bis(2-pyrrolyl)ethenes"; Xie, H; Lee, D.A.; Wallace, D.M.; Senge, M.O.; Smith, K.M. J.  Org. Chem. 1996, 61(24), 8508-8517.
10. "Rational Tetraarylporphyrin Syntheses: Tetraarylporphyrins from the MacDonald Route"; Wallace, D.M.; Leung, S.H.; Senge, M.O.; Smith, K.M. J.  Org. Chem. 1993, 58(25), 7245-7257.
11. "Stepwise Syntheses of Unsymmetrical Tetra-arylporphyrins. Adaptation of the MacDonald Dipyrrole Self-condensation Methodology"; Wallace, D. M.; Smith, K. M.   Tetrahedron Lett. 1990, 31(50), 7265-7268.

 

pRESENTATIONs

1. "Improved synthesis and chemical modification of a beta-O-4 type artificial lignin polymer";Iovine, P.M.; Wallace, D.   Presented at the 236th American Chemical Society National Meeting, Philadelphia, PA, August 17-21, 2008.
2. "Malonyl CoA Decarboxylase is a Major Regulator of Cardiac Fatty acid Oxidation", Dyck, J.R.B.; Cheng, J.-F.; Stanley, W.C.; Barr, R.; Margaret P. Chandler, M.P.; Steven Brown, S.; Wallace, D.; Arrhenius, T.; Harmon, C.; Guang Yang, G.; Alex Nadzan, A.; Lopaschuk, G.D.  Presented at the American Heart Association, Scientific Sessions 2003 in Orlando, Florida, November 10, 2003.
3. "Phosphorothioate Oligonucleotides with Significant Anti-HIV Activity"; Sridhar, C.N.; Patel, J.; Wallace, D.; Batranina, M.; Serafimov, R.; Kwoh, J.; Whalley, A.; Miners, D.; Ryder, T.; Dattagupta, N.   Presented at the 210th American Chemical Society National Meeting, Chicago, Illinois, August 20, 1995.
4. "GPs0193, A Phosphorothioate Oligonucleotide with Significant Activity Against Human Immunodeficiency Virus"; Sridhar, C.N.; Patel, J.; Wallace, D.; Ni, J.; Aiyar, J.; Das, A.; Batranina, M.; Serafimov, R.; Hall, T.; Dattagupta, N.   Presented at the Western Biotech Conference, San Diego, California, October 18, 1995.